Viberzi denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Viberzi Under Step Therapy

A step-therapy denial means Cigna requires you to try and fail one or more preferred (usually lower-cost) medications before it will approve coverage of Viberzi (eluxadoline) for IBS-D. Step-therapy protocols are common for branded specialty drugs. The denial does not mean Viberzi is inappropriate for you — it means the plan needs evidence that the required earlier steps were completed, or that they cannot be.

This denial is frequently overturned when the required step-therapy history is properly documented, or when a clinical exception applies (such as a contraindication to or prior failure on every required step).

## Why This Denial Is Appealable

Many states have enacted step-therapy exception laws requiring insurers to honor step-therapy exceptions when a required drug was previously tried and failed, is contraindicated, or would cause clinically significant harm. Even in states without such laws, Cigna's own policy typically includes an exception pathway. If you have already failed the required steps, the denial may simply reflect a documentation gap rather than a genuine policy bar.

## Your Federal Appeal Rights

Under ACA §2719, step-therapy denials are subject to internal appeal and independent external review by an accredited IRO. Under ERISA §503, self-funded employer plans must provide full-and-fair review. The external-review window is generally approximately four months from the denial notice. Expedited review is available in urgent situations.

## The Appeal Process

1. Identify the required steps. Request from Cigna the exact step-therapy requirements — specifically which drugs must be tried, in what order, and for what duration, before Viberzi is approved. 2. Step-therapy exception request. If required steps were already tried, or if your prescriber can document a clinical reason a step cannot be completed, submit a step-therapy exception request concurrently with or before the formal appeal. 3. Level 1 internal appeal. Submit within the appeal deadline with the complete documentation package. 4. External review. If denied internally, escalate to independent external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing IBS-D.
• Step-therapy history: For each required prior drug, provide: drug name, start date, end date, clinical response (or adverse event), and the treating clinician's documented assessment.
• Exception basis documentation: If a required step is clinically inappropriate, a prescriber letter explaining the clinical reason with chart support.
• Prescriber medical-necessity letter: Addresses the step-therapy criteria point by point, explains why the required steps are complete or cannot be completed, and supports Viberzi as the appropriate next therapy.

## Criteria-Mapping Structure

Obtain Cigna's step-therapy policy for eluxadoline/Viberzi. For each required step, create a table row: required drug | dates tried | documented outcome | source in chart. Where an exception applies, cite the specific exception criterion from Cigna's policy and the chart fact supporting it. Confirm any duration or failure criteria against both Cigna's published policy and the FDA-approved prescribing label.